Keybank National Association OH Sells 75,877 Shares of Pfizer Inc. (NYSE:PFE)

Keybank National Association OH reduced its stake in Pfizer Inc. (NYSE:PFE) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,609,917 shares of the biopharmaceutical company’s stock after selling 75,877 shares during the quarter. Keybank National Association OH’s holdings in Pfizer were worth $42,711,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in PFE. Ariston Services Group acquired a new position in shares of Pfizer during the fourth quarter worth $269,000. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Bedel Financial Consulting Inc. boosted its stake in Pfizer by 18.1% in the fourth quarter. Bedel Financial Consulting Inc. now owns 34,824 shares of the biopharmaceutical company’s stock valued at $921,000 after acquiring an additional 5,329 shares during the last quarter. Auxano Advisors LLC lifted its stake in shares of Pfizer by 17.0% during the 4th quarter. Auxano Advisors LLC now owns 24,427 shares of the biopharmaceutical company’s stock valued at $648,000 after buying an additional 3,553 shares in the last quarter. Finally, Woodley Farra Manion Portfolio Management Inc. increased its holdings in Pfizer by 3.7% during the 4th quarter. Woodley Farra Manion Portfolio Management Inc. now owns 84,259 shares of the biopharmaceutical company’s stock worth $2,235,000 after acquiring an additional 3,028 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.21 on Tuesday. The business has a 50-day simple moving average of $26.34 and a 200-day simple moving average of $27.30. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $148.53 billion, a PE ratio of 18.59, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company earned $0.10 earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Guggenheim reissued a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.